Maravai LifeSciences Holdings, Inc.
US ˙ NasdaqGS ˙ US56600D1072

Introduction

This page provides a comprehensive analysis of the known insider trading history of Carl Hull. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Carl Hull has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:MRVI / Maravai LifeSciences Holdings, Inc. See Remarks, Director 175,000
US:OCDX / Ortho Clinical Diagnostics Holdings plc Director 0
US:HOLX / Hologic, Inc. SVP and GM of Diagnostics 61,674
Chairman and CEO, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Carl Hull. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases MRVI / Maravai LifeSciences Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MRVI / Maravai LifeSciences Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-11-11 MRVI HULL CARL 175,000 5.6400 175,000 5.6400 987,000 58 6.1300 85,750 8.69
2020-11-25 MRVI HULL CARL 35,000 26.9400 35,000 26.9400 942,900

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRVI / Maravai LifeSciences Holdings, Inc. Insider Trades
Insider Sales MRVI / Maravai LifeSciences Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MRVI / Maravai LifeSciences Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRVI / Maravai LifeSciences Holdings, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Carl Hull as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-11-12 2024-11-11 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
P - Purchase 175,000 175,000 5.64 987,000 987,000
2024-03-18 2024-03-15 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
F - Taxes -17,560 267,072 -6.17 7.70 -135,212 2,056,454
2024-02-20 2024-02-15 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
F - Taxes -10,729 284,632 -3.63 5.48 -58,795 1,559,783
2024-01-18 2024-01-16 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
A - Award 75,842 295,361 34.55
2023-03-17 2023-03-15 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
A - Award 147,638 219,519 205.39
2023-02-17 2023-02-15 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
F - Taxes -9,719 71,881 -11.91 15.23 -148,020 1,094,748
2022-06-01 2022-05-27 4 OCDX Ortho Clinical Diagnostics Holdings plc
Ordinary Shares, $0.00001 par value
D - Sale to Issuer -41,172 0 -100.00
2022-06-01 2022-05-27 4 OCDX Ortho Clinical Diagnostics Holdings plc
Ordinary Shares, $0.00001 par value
D - Sale to Issuer -21,011 0 -100.00
2022-01-27 2022-01-25 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Employee Stock Options (Right to Buy)
A - Award 151,200 151,200
2022-01-27 2022-01-25 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
A - Award 81,600 81,600
2021-05-05 2021-05-03 4 OCDX Ortho Clinical Diagnostics Holdings plc
Ordinary Shares
A - Award 2,600 21,011 14.12
2021-01-27 3 OCDX Ortho Clinical Diagnostics Holdings plc
Ordinary Shares
18,411
2021-01-27 3 OCDX Ortho Clinical Diagnostics Holdings plc
Ordinary Shares
41,172
2020-11-30 2020-11-25 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Class A Common Stock
P - Purchase 35,000 35,000 26.94 942,900 942,900
2020-11-23 2020-11-19 4 MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Employee Stock Options (Right to Buy)
A - Award 60,000 60,000
2013-02-05 2013-02-01 4 HOLX HOLOGIC INC
Common Stock
F - Taxes -81,729 61,674 -56.99 23.72 -1,938,612 1,462,907
2012-11-15 2012-11-14 4 HOLX HOLOGIC INC
Non-qualified Stock Option (Right to Buy)
A - Award 28,050 28,050 19.86 557,073 557,073
2012-11-15 2012-11-14 4 HOLX HOLOGIC INC
Common Stock
A - Award 10,070 143,403 7.55
2012-08-02 2012-08-01 4 HOLX HOLOGIC INC
Common Stock
A - Award 133,333 133,333
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Performance Stock Rights
D - Sale to Issuer -40,000 0 -100.00
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Performance Stock Rights
D - Sale to Issuer -10,001 0 -100.00
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -110,000 0 -100.00
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -112,500 0 -100.00 18.95 -2,131,875
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -105,000 0 -100.00 40.09 -4,209,450
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -19,480 0 -100.00 39.03 -760,304
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -37,500 0 -100.00 22.60 -847,500
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -35,000 0 -100.00 21.93 -767,550
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
D - Sale to Issuer -62,188 0 -100.00 35.33 -2,197,102
2012-08-02 2012-08-01 4 GPRO GEN PROBE INC
Common Stock
D - Sale to Issuer -47,044 0 -100.00 82.75 -3,892,891
2012-04-19 2012-04-17 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
M - Exercise X -7,083 62,188 -10.23
2012-04-19 2012-04-17 4 GPRO GEN PROBE INC
Common Stock
S - Sale X -1,200 46,967 -2.49 66.65 -79,980 3,130,351
2012-04-19 2012-04-17 4 GPRO GEN PROBE INC
Common Stock
S - Sale X -5,883 48,167 -10.88 66.23 -389,631 3,190,100
2012-04-19 2012-04-17 4 GPRO GEN PROBE INC
Common Stock
M - Exercise X 7,083 54,050 15.08 47.42 335,876 2,563,051
2012-03-20 2012-03-16 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
M - Exercise X -5,729 69,271 -7.64
2012-03-20 2012-03-16 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
M - Exercise X -6,354 19,480 -24.60
2012-03-20 2012-03-16 4 GPRO GEN PROBE INC
Common Stock
S - Sale X -12,083 46,967 -20.46 66.56 -804,244 3,126,124
2012-03-20 2012-03-16 4 GPRO GEN PROBE INC
Common Stock
M - Exercise X 5,729 59,050 10.74 47.42 271,669 2,800,151
2012-03-20 2012-03-16 4 GPRO GEN PROBE INC
Common Stock
M - Exercise X 6,354 53,321 13.53 43.72 277,797 2,331,194
2012-02-17 2012-02-16 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
M - Exercise X -12,083 25,834 -31.87
2012-02-17 2012-02-16 4 GPRO GEN PROBE INC
Common Stock
S - Sale X -12,083 46,967 -20.46 69.14 -835,419 3,247,298
2012-02-17 2012-02-16 4 GPRO GEN PROBE INC
Common Stock
M - Exercise X 12,083 59,050 25.73 43.72 528,269 2,581,666
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Performance Stock Rights
M - Exercise -5,948 10,001 -37.29
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Performance Stock Rights
A - Award 949 15,949 6.33
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Common Stock
F - Taxes -719 46,967 -1.51 69.22 -49,769 3,251,056
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Common Stock
F - Taxes -1,966 47,686 -3.96 69.22 -136,087 3,300,825
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Common Stock
M - Exercise 5,948 49,652 13.61
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Performance Stock Rights
A - Award 40,000 40,000
2012-02-14 2012-02-10 4 GPRO GEN PROBE INC
Stock Options (Right to Buy)
A - Award 110,000 110,000
2012-01-19 2012-01-17 4 GPRO GEN PROBE INC
Stock Option (Right to Buy)
M - Exercise X -17,083 37,917 -31.06
2012-01-19 2012-01-17 4 GPRO GEN PROBE INC
Common Stock
S - Sale X -17,083 43,704 -28.10 60.86 -1,039,654 2,659,782
2012-01-19 2012-01-17 4 GPRO GEN PROBE INC
Common Stock
M - Exercise X 17,083 60,787 39.09 43.72 746,869 2,657,608
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)